Gut hormone leads to weight loss in overweight or obese patients

Giving overweight or obese patients a gut hormone that suppresses appetite leads to clinically beneficial weight loss as well as reduced blood pressure and cholesterol levels, finds a study published in the British Medical Journal today.

Glucagon-like peptide-1 (GLP-1) is a hormone that is secreted from the intestine when we eat. GLP-1 based therapy was recently introduced as a new treatment for patients with because of its ability to regulate .

But it also suppresses food intake and appetite, making it an interesting approach in the treatment of obesity.

So researchers at the University of Copenhagen set out to determine the effect of glucagon-like peptide-1 receptor (GLP-1R) on weight loss. They also looked at their effect on blood pressure, cholesterol and liver enzyme levels, and blood sugar (glycaemic) control.

They analysed the results of 25 involving over 6,000 patients. Differences in study design and quality were taken into account to minimise bias.

They found that patients who received clinically relevant doses of GLP-1R agonists for at least 20 weeks achieved a greater weight loss compared with the control groups.

The benefit was seen for patients with and without type 2 diabetes, but may be more pronounced in patients without diabetes.

GLP-1R agonists also had beneficial effects on blood pressure, cholesterol and improved glycaemic control in patients with type 2 diabetes. There was no statistically significant effect on .

Common side effects included nausea, vomiting and diarrhoea, but did not seem to affect the number of patients dropping out of the trials, suggesting that overall with the treatment is relatively high.

The authors say that their analysis "provides convincing evidence that GLP-1R agonists, when given to obese patients with or without diabetes, result in clinically relevant beneficial effects on body weight. Additional beneficial effects on blood pressure and total cholesterol might also be achieved."

They believe that the intervention "should be considered in patients with diabetes who are obese or overweight" and call for further studies "to elucidate the effects of GLP-1R agonists in the treatment of obese patients without diabetes."

While these results highlight the weight-reducing benefits of GLP-1 agonists, they should not alter current practice, says Professor Raj Padwal from the University of Alberta in an accompanying editorial. He argues that "modification of diet and lifestyle remains the cornerstone of the treatment of type 2 diabetes."

He also points out that the safety of GLP-1 agonists is still unknown and says "continued and close surveillance of these new agents using all available data sources is warranted."

Related Stories

Improving psoriasis with GLP-1 analogue therapy

Dec 13, 2011

(Medical Xpress) -- UCD clinician scientists and researchers from NUI Maynooth and Trinity College led by Conway Fellow, Professor Donal O’Shea have reported an improvement in the severity of psoriasis in patients following ...

A new molecule to combat diabetes and obesity

Sep 01, 2009

Type 2 diabetes, the most common form of diabetes, is increasing at an alarming state with more than 180 million people affected worldwide. With the rising incidence of obesity, a major risk factor for the onset of type 2 ...

Welsh medics to examine how surgery can cure diabetes

May 31, 2007

Scientists at Swansea University’s School of Medicine have been awarded more than £93,000 by the BUPA Foundation to investigate why weight-reducing surgery can lead to the almost immediate disappearance of diabetes in ...

Recommended for you

Nearly 30% of world population is overweight: study

Nov 20, 2014

More than 2.1 billion people globally—or nearly 30 percent of the world's population—are now overweight or obese, with the figure set to rise further by 2030, according to a study published Thursday.

Report: Global obesity costs hits $2 trillion

Nov 20, 2014

The global cost of obesity has risen to $2 trillion annually—nearly as much as smoking or the combined impact of armed violence, war and terrorism, according to a new report released Thursday.

Small cash rewards pay off in weight loss plans

Nov 20, 2014

People who received small cash bonuses for their degree of participation in an Internet weight loss program shed more pounds than those who were not offered bonuses and they kept much of the weight off, according to a new ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Hospital Management
not rated yet Jan 10, 2012
If there is Overweight problem due to medical complications then how to loss weight..

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.